Organ Transplant Rejection Medication Market

Organ Transplant Rejection Medication Market (Drug Class: Antibodies, Antimetabolites, Calcineurin Inhibitors, mTOR Inhibitors, and Steroids; Transplant Type: Kidney, Liver, Heart, Lung, Pancreas, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031

Global Organ Transplant Rejection Medication Market Outlook

  • The global industry was valued at US$ 4.9 Bn in 2022
  • It is projected to grow at a CAGR of 3.9% from 2023 to 2031 and reach more than US$ 7.0 Bn by the end of 2031

Analysts’ Viewpoint

Rise in prevalence of chronic diseases and increase in incidence of organ failure, which requires organ transplantation, are driving the global organ transplant rejection medication market. Advancements in transplant technology and aging population have led to a surge in the number of transplant procedures, which is driving demand for immunosuppressive drugs. Furthermore, increase in awareness about the benefits of organ transplantation, favorable reimbursement policies, and rise in number of organ donors are propelling market development.

Research & development in new and more effective immunosuppressive drugs offers lucrative opportunities to market players. Companies are focusing on expanding to emerging economies, such as China, India, Brazil, and South Africa, in order to increase market share and revenue.

Organ Transplant Rejection Medication Market

Global Organ Transplant Rejection Medication Market Introduction

Organ transplantation has emerged as a promising therapeutic option for patients suffering from organ failure, offering them an extended lifespan and improved quality of life. Despite advances in transplantation techniques and development of immunosuppressive drugs, organ rejection remains a significant concern.

Organ rejection occurs when the recipient's immune system recognizes the transplanted organ as foreign and mounts an attack against it, leading to graft failure. In order to prevent rejection and ensure long-term success of transplantation, patients are required to take immunosuppressive medications that dampen their immune system's response to the transplant.

The organ transplant rejection medication industry includes drugs that are used to prevent and treat organ rejection in transplant recipients. The market has witnessed significant developments in the past few years, including development of newer immunosuppressive agents with improved efficacy and safety profiles, and introduction of novel treatment modalities such as cell-based therapies and gene editing.

Increase in demand for organ transplantation and continued research to advance the field of transplantation medicine are expected to propel global organ transplant rejection medication market value.

Increase in Incidence of Organ Failure Globally

Organ failure is a serious medical condition that occurs when one or more vital organs in the body stop functioning correctly. This can happen due to reasons such as illness, injury, or genetic disorders, and is a leading cause of death globally. Incidence of organ failure is increasing due to factors such as an aging population, unhealthy lifestyle choices, and environmental pollution.

Demand for organ transplantation is rising owing to surge in cases of organ failure. In 2017, the World Health Organization (WHO) estimated that 10% of the world's population suffered from chronic kidney disease, putting over 700 million people at risk of developing kidney failure. In the U.S., more than 112,000 people are waiting for an organ transplant, with the majority of them waiting for a kidney transplant.

The Global Observatory on Donation and Transplantation reported that over 140,000 organ transplants were performed worldwide in 2019, with kidneys being the most commonly transplanted organ due to factors such as aging population, diabetes, high blood pressure, obesity, and unhealthy lifestyle factors, such as smoking.

Heart failure is another factor fueling global organ transplant rejection medication market demand. According to WHO, an estimated 17.9 million people succumb to cardiovascular disorders (CVD) each year.

Rise in Global Geriatric Population

Aging increases the need for health care, as it renders people prone to cardiovascular diseases, such as coronary heart disease, respiratory diseases, such as TB and pneumonia, dental caries, oral cancer, and orthopedic conditions, such as osteoporosis. Rise in prevalence of these diseases is likely to widen the target patient pool for organ transplant.

According to the WHO, the global geriatric population is likely to reach around 2 billion (22% of global population) by 2050, as against 524 million in 2010. Hence, rapidly aging global population is anticipated to augment global organ transplant rejection medication market size.

According to WHO estimates, the geriatric population is expected to rise at a rapid pace in developed countries such as the U.S., the U.K., and Japan. Around 82% of people who succumb to a coronary artery disease are aged 65 years and above.

Access to several diagnostic and treatment services has improved due to favorable healthcare policies and advancements in healthcare facilities in countries such as the U.S., Japan, the U.K., and other countries in Western Europe, which in turn has increased the life expectancy of the population.

Hence, surge in the geriatric population is anticipated to propel global organ transplant rejection medication market development during the forecast period.

Adequate Immunosuppression and Less Side-effects Fueling Calcineurin Inhibitors Segment

In terms of drug class, the calcineurin inhibitors segment accounted for the largest global organ transplant rejection medication market share in 2022. Rise in preference for calcineurin inhibitors due to adequate immunosuppression and less side-effects compared to other classes is likely to propel the segment during the forecast period.

Calcineurin inhibitors (CNIs) have been the cornerstone of immunosuppressive therapy for organ transplant recipients for over 30 years. CNIs, including cyclosporine and tacrolimus, work by inhibiting the activity of calcineurin, a key enzyme in the T-cell signaling pathway that triggers the immune response.

The primary reason for widespread usage of CNIs is their effectiveness in preventing acute rejection of transplanted organs. These significantly reduce the incidence of acute rejection episodes, thereby improving the long-term outcome of organ transplantation. Furthermore, CNIs have been associated with improved graft survival rates compared to other organ transplant immunosuppressants, also known as transplantation immunosuppressants.

Another advantage of CNIs is broad spectrum of activity against both T- and B-cell-mediated immune responses, which makes them useful for a range of organ transplant types. These are also available in various formulations, including oral and injectable versions, making them easy to administer to patients.

High Success Rate of Kidney Transplant

Based on transplant type, the kidney transplant segment dominated the global market in 2022. Kidney transplant is the most common type of organ transplant performed globally, with a high success rate. Availability of living donors, including family members and unrelated donors, has increased the number of kidney transplants performed.

Living donor transplants have higher success rates, and the risk of rejection is lower compared to deceased donor transplants. This has contributed to the popularity of kidney transplantation.

Advances in medical technology have made kidney transplantation safer and more successful. New surgical techniques, immunosuppressive drugs, and better diagnostic tools have contributed to rise in successful kidney transplants.

According to WHO, 144,302 transplant surgeries were performed in 2021, with the majority being kidney transplant (92,532), followed by liver transplant (34,694), heart transplant (8,409), lung transplant (6,470), pancreas transplant (2,025), and small bowel transplant (172).

Timely Availability and Convenience Bolstering Retail Pharmacies Segment

In terms of distribution channel, the retail pharmacies segment accounted for the largest share of the global market 2022.

Several patients prefer retail pharmacies due to timely availability and convenience in terms of purchase of medications associated with retail pharmacies. Rise in number of patients opting for retail pharmacies due to large number of product brands available at discounted prices is likely to drive the segment during the forecast period.

Staff at retail pharmacies is trained and knowledgeable about medications, providing patients with advice and information about their prescriptions. These pharmacies often have established relationships with healthcare providers and insurance companies, facilitating smooth processing of prescriptions and insurance claims.

Retail pharmacies can benefit from economies of scale by purchasing medications in bulk, which can translate into lower prices for patients.

Regional Outlook

According to organ transplant rejection medication market trends, North America dominated the global industry in 2022. This is ascribed to presence of large number of living as well as deceased donors and better organ-preserving practices in the region.

The market in North America is driven by high incidence of chronic diseases. Rapid adoption of advanced treatment options in the health care sector for treating various diseases is also expected to propel the market in the region during the forecast period. However, high cost and complex procedures are likely to hamper the market in the region during the forecast period.

Increase in the geriatric population is a major concern in Europe, as elderly individuals are more prone to organ dysfunction. The European Commission (Eurostat) has estimated that the geriatric population in Europe could reach 525 million by 2035. Rise in the geriatric population is likely to propel the demand for organ transplant rejection medications in the region during the forecast period.

Developing countries in Asia Pacific are generic-driven markets due to cost-constraints. Increase in competition from generic drugs leading to reduced drug prices and rise in affordability and awareness among patients are expected to propel the organ transplant rejection medications market in the region.

Analysis of Key Players

The global market is fragmented, with the presence of large number of players. Companies in the organ transplant rejection medication market are Pfizer, Inc., Astellas Pharma, Inc., Novartis AG, F. Hoffmann-La Roche Ltd., Sanofi, Bristol-Myers Squibb Company, GlaxoSmithKline plc, AbbVie, Inc., Hansa Biopharma, WOCKHARDT, Viatris, Inc., Glenmark, Biocon, Hikma Pharmaceuticals plc, Teva Pharmaceutical U.S.A, Inc., and Zydus Pharmaceuticals.

Key Developments in Global Organ Transplant Rejection Medication Market

  • In July 2021, Astellas Pharma, Inc. received approval from the U.S. FDA for its supplemental New Drug Application (sNDA) of PROGRAF (tacrolimus) to prevent organ rejection in both adult and pediatric recipients of lung transplants
  • In February 2023, final approval for Sirolimus Tablets, in strengths of 1 mg and 2 mg, was granted to Zydus Lifesciences by the U.S. FDA.

Each of these players has been profiled in the organ transplant rejection medication market report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.

Global Organ Transplant Rejection Medication Market Snapshot

Attribute Detail

Size in 2022

US$ 4.9 Bn

Forecast Value in 2031

More than US$ 7.0 Bn

CAGR

3.9%

Forecast Period

2023-2031

Historical Data Available for

2017-2021

Quantitative Units

US$ Bn for Value

Market Analysis

It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis.

Competition Landscape

  • Market share analysis by company (2022)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials

Format

Electronic (PDF) + Excel

Segmentation

  • Drug Class
    • Antibodies
    • Antimetabolites
    • Calcineurin Inhibitors
    • mTOR Inhibitors
    • Steroids
  • Transplant Type
    • Kidney
    • Liver
    • Heart
    • Lung
    • Pancreas
    • Others
  • Distribution Channel
    • Hospitals Pharmacies
    • Retail Pharmacies
    • Online Pharmacies

Regions Covered

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa

Countries Covered

  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • China
  • India
  • Japan
  • Australia & New Zealand
  • Brazil
  • Mexico
  • GCC Countries
  • South Africa

Companies Profiled

  • Pfizer, Inc.
  • Astellas Pharma, Inc.
  • Novartis AG
  • F. Hoffmann-La Roche Ltd.
  • Sanofi
  • Bristol-Myers Squibb Company
  • GlaxoSmithKline plc
  • AbbVie, Inc.
  • Hansa Biopharma
  • WOCKHARDT
  • Viatris, Inc.
  • Glenmark
  • Biocon
  • Hikma Pharmaceuticals plc
  • Teva Pharmaceutical U.S.A Inc.
  • Zydus Pharmaceuticals, Inc.

Customization Scope

Available upon request

Pricing

Available upon request

Frequently Asked Questions

How big was the global organ transplant rejection medication market in 2022?

The global industry was valued at US$ 4.9 Bn in 2022

How big will be the organ transplant rejection medication industry size in 2031?

It is projected to reach more than US$ 7.0 Bn by 2031

What will be the CAGR of the organ transplant rejection medication business during the forecast period?

The market is anticipated to grow at a CAGR of 3.9% from 2023 to 2031

What was the market share of the leading segment of the organ transplant rejection medication?

The kidney segment held more than 60.0% share in 2022

Which region will account for major share of the organ transplant rejection medication during the forecast period?

North America is expected to account for largest market share from 2022 to 2031

Who are the prominent organ transplant rejection medication players?

Pfizer, Inc., Astellas Pharma, Inc., Novartis AG, F. Hoffmann-La Roche Ltd., Sanofi, Bristol-Myers Squibb Company, GlaxoSmithKline plc, AbbVie, Inc., Hansa Biopharma, WOCKHARDT, Viatris, Inc., Glenmark, Biocon, Hikma Pharmaceuticals plc, Teva Pharmaceutical U.S.A Inc., and Zydus Pharmaceuticals are the prominent players operating in the market.

    1. Preface

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: Global Organ Transplant Rejection Medication Market

    4. Market Overview

        4.1. Introduction

            4.1.1. Segment Definition

        4.2. Overview

        4.3. Market Dynamics

            4.3.1. Drivers

            4.3.2. Restraints

            4.3.3. Opportunities

        4.4. Global Organ Transplant Rejection Medication Market Analysis and Forecast, 2017-2031

    5. Key Insights

        5.1. Current Global Scenario: Organ Donation for Transplantation

        5.2. Key Product/Brand Analysis

        5.3. Pipeline Analysis

        5.4. COVID-19 Impact Analysis

    6. Global Organ Transplant Rejection Medication Market Analysis and Forecast, by Drug Class

        6.1. Introduction & Definition

        6.2. Key Findings/Developments

        6.3. Market Value Forecast, by Drug Class, 2017-2031

            6.3.1. Antibodies

                6.3.1.1. Thymoglobulin

                6.3.1.2. Alemtuzumab

                6.3.1.3. Belatacept

                6.3.1.4. Muromonab-CD3

                6.3.1.5. Basiliximab

                6.3.1.6. Eculizumab

            6.3.2. Antimetabolites

                6.3.2.1. Azathioprine

                6.3.2.2. Mycophenolate Mofetil

                6.3.2.3. Mycophenolate sodium, MPA

            6.3.3. Calcineurin Inhibitors

                6.3.3.1. Cyclosporine

                6.3.3.2. Tacrolimus

            6.3.4. mTOR Inhibitors

                6.3.4.1. Sirolimus

                6.3.4.2. Everolimus

            6.3.5. Steroids

                6.3.5.1. Prednisolone

                6.3.5.2. Methylprednisolone

        6.4. Market Attractiveness Analysis, by Drug Class

    7. Global Organ Transplant Rejection Medication Market Analysis and Forecast, by Transplant Type

        7.1. Introduction & Definition

        7.2. Key Findings/Developments

        7.3. Market Value Forecast, by Transplant Type, 2017-2031

            7.3.1. Kidney

            7.3.2. Liver

            7.3.3. Heart

            7.3.4. Lung

            7.3.5. Pancreas

            7.3.6. Others

        7.4. Market Attractiveness Analysis, by Transplant Type

    8. Global Organ Transplant Rejection Medication Market Analysis and Forecast, by Distribution Channel

        8.1. Introduction & Definition

        8.2. Key Findings/Developments

        8.3. Market Value Forecast, by Distribution Channel, 2017-2031

            8.3.1. Hospital Pharmacies

            8.3.2. Retail Pharmacies

            8.3.3. Online Pharmacies

        8.4. Market Attractiveness Analysis, by Distribution Channel

    9. Global Organ Transplant Rejection Medication Market Analysis and Forecast, by Region

        9.1. Key Findings

        9.2. Market Value Forecast, by Region, 2017-2031

            9.2.1. North America

            9.2.2. Europe

            9.2.3. Asia Pacific

            9.2.4. Latin America

            9.2.5. Middle East & Africa

        9.3. Market Attractiveness Analysis, by Region

    10. North America Organ Transplant Rejection Medication Market Analysis and Forecast

        10.1. Introduction

            10.1.1. Key Findings

        10.2. Market Value Forecast, by Drug Class, 2017-2031

            10.2.1. Antibodies

                10.2.1.1. Thymoglobulin

                10.2.1.2. Alemtuzumab

                10.2.1.3. Belatacept

                10.2.1.4. Muromonab-CD3

                10.2.1.5. Basiliximab

                10.2.1.6. Eculizumab

            10.2.2. Antimetabolites

                10.2.2.1. Azathioprine

                10.2.2.2. Mycophenolate Mofetil

                10.2.2.3. Mycophenolate sodium, MPA

            10.2.3. Calcineurin Inhibitors

                10.2.3.1. Cyclosporine

                10.2.3.2. Tacrolimus

            10.2.4. mTOR Inhibitors

                10.2.4.1. Sirolimus

                10.2.4.2. Everolimus

            10.2.5. Steroids

                10.2.5.1. Prednisolone

                10.2.5.2. Methylprednisolone

        10.3. Market Value Forecast, by Transplant Type, 2017-2031

            10.3.1. Kidney

            10.3.2. Liver

            10.3.3. Heart

            10.3.4. Lung

            10.3.5. Pancreas

            10.3.6. Others

        10.4. Market Value Forecast, by Distribution Channel, 2017-2031

            10.4.1. Hospital Pharmacies

            10.4.2. Retail Pharmacies

            10.4.3. Online Pharmacies

        10.5. Market Value Forecast, by Country, 2017-2031

            10.5.1. U.S.

            10.5.2. Canada

        10.6. Market Attractiveness Analysis

            10.6.1. By Drug Class

            10.6.2. By Transplant Type

            10.6.3. By Distribution Channel

            10.6.4. By Country

    11. Europe Organ Transplant Rejection Medication Market Analysis and Forecast

        11.1. Introduction

            11.1.1. Key Findings

        11.2. Market Value Forecast, by Drug Class, 2017-2031

            11.2.1. Antibodies

                11.2.1.1. Thymoglobulin

                11.2.1.2. Alemtuzumab

                11.2.1.3. Belatacept

                11.2.1.4. Muromonab-CD3

                11.2.1.5. Basiliximab

                11.2.1.6. Eculizumab

            11.2.2. Antimetabolites

                11.2.2.1. Azathioprine

                11.2.2.2. Mycophenolate Mofetil

                11.2.2.3. Mycophenolate sodium, MPA

            11.2.3. Calcineurin Inhibitors

                11.2.3.1. Cyclosporine

                11.2.3.2. Tacrolimus

            11.2.4. mTOR Inhibitors

                11.2.4.1. Sirolimus

                11.2.4.2. Everolimus

            11.2.5. Steroids

                11.2.5.1. Prednisolone

                11.2.5.2. Methylprednisolone

        11.3. Market Value Forecast, by Transplant Type, 2017-2031

            11.3.1. Kidney

            11.3.2. Liver

            11.3.3. Heart

            11.3.4. Lung

            11.3.5. Pancreas

            11.3.6. Others

        11.4. Market Value Forecast, by Distribution Channel, 2017-2031

            11.4.1. Hospital Pharmacies

            11.4.2. Retail Pharmacies

            11.4.3. Online Pharmacies

        11.5. Market Value Forecast, by Country/Sub-region, 2017-2031

            11.5.1. Germany

            11.5.2. U.K.

            11.5.3. France

            11.5.4. Italy

            11.5.5. Spain

            11.5.6. Rest of Europe

        11.6. Market Attractiveness Analysis

            11.6.1. By Drug Class

            11.6.2. By Transplant Type

            11.6.3. By Distribution Channel

            11.6.4. By Country/Sub-region

    12. Asia Pacific Organ Transplant Rejection Medication Market Analysis and Forecast

        12.1. Introduction

            12.1.1. Key Findings

        12.2. Market Value Forecast, by Drug Class, 2017-2031

            12.2.1. Antibodies

                12.2.1.1. Thymoglobulin

                12.2.1.2. Alemtuzumab

                12.2.1.3. Belatacept

                12.2.1.4. Muromonab-CD3

                12.2.1.5. Basiliximab

                12.2.1.6. Eculizumab

            12.2.2. Antimetabolites

                12.2.2.1. Azathioprine

                12.2.2.2. Mycophenolate Mofetil

                12.2.2.3. Mycophenolate sodium, MPA

            12.2.3. Calcineurin Inhibitors

                12.2.3.1. Cyclosporine

                12.2.3.2. Tacrolimus

            12.2.4. mTOR Inhibitors

                12.2.4.1. Sirolimus

                12.2.4.2. Everolimus

            12.2.5. Steroids

                12.2.5.1. Prednisolone

                12.2.5.2. Methylprednisolone

        12.3. Market Value Forecast, by Transplant Type, 2017-2031

            12.3.1. Kidney

            12.3.2. Liver

            12.3.3. Heart

            12.3.4. Lung

            12.3.5. Pancreas

            12.3.6. Others

        12.4. Market Value Forecast, by Distribution Channel, 2017-2031

            12.4.1. Hospital Pharmacies

            12.4.2. Retail Pharmacies

            12.4.3. Online Pharmacies

        12.5. Market Value Forecast, by Country/Sub-region, 2017-2031

            12.5.1. China

            12.5.2. Japan

            12.5.3. India

            12.5.4. Australia & New Zealand

            12.5.5. Rest of Asia Pacific

        12.6. Market Attractiveness Analysis

            12.6.1. By Drug Class

            12.6.2. By Transplant Type

            12.6.3. By Distribution Channel

            12.6.4. By Country/Sub-region

    13. Latin America Organ Transplant Rejection Medication Market Analysis and Forecast

        13.1. Introduction

            13.1.1. Key Findings

        13.2. Market Value Forecast, by Drug Class, 2017-2031

            13.2.1. Antibodies

                13.2.1.1. Thymoglobulin

                13.2.1.2. Alemtuzumab

                13.2.1.3. Belatacept

                13.2.1.4. Muromonab-CD3

                13.2.1.5. Basiliximab

                13.2.1.6. Eculizumab

            13.2.2. Antimetabolites

                13.2.2.1. Azathioprine

                13.2.2.2. Mycophenolate Mofetil

                13.2.2.3. Mycophenolate sodium, MPA

            13.2.3. Calcineurin Inhibitors

                13.2.3.1. Cyclosporine

                13.2.3.2. Tacrolimus

            13.2.4. mTOR Inhibitors

                13.2.4.1. Sirolimus

                13.2.4.2. Everolimus

            13.2.5. Steroids

                13.2.5.1. Prednisolone

                13.2.5.2. Methylprednisolone

        13.3. Market Value Forecast, by Transplant Type, 2017-2031

            13.3.1. Kidney

            13.3.2. Liver

            13.3.3. Heart

            13.3.4. Lung

            13.3.5. Pancreas

            13.3.6. Others

        13.4. Market Value Forecast, by Distribution Channel, 2017-2031

            13.4.1. Hospital Pharmacies

            13.4.2. Retail Pharmacies

            13.4.3. Online Pharmacies

        13.5. Market Value Forecast, by Country/Sub-region, 2017-2031

            13.5.1. Brazil

            13.5.2. Mexico

            13.5.3. Rest of Latin America

        13.6. Market Attractiveness Analysis

            13.6.1. By Drug Class

            13.6.2. By Transplant Type

            13.6.3. By Distribution Channel

            13.6.4. By Country/Sub-region

    14. Middle East & Africa Organ Transplant Rejection Medication Market Analysis and Forecast

        14.1. Introduction

            14.1.1. Key Findings

        14.2. Market Value Forecast, by Drug Class, 2017-2031

            14.2.1. Antibodies

                14.2.1.1. Thymoglobulin

                14.2.1.2. Alemtuzumab

                14.2.1.3. Belatacept

                14.2.1.4. Muromonab-CD3

                14.2.1.5. Basiliximab

                14.2.1.6. Eculizumab

            14.2.2. Antimetabolites

                14.2.2.1. Azathioprine

                14.2.2.2. Mycophenolate Mofetil

                14.2.2.3. Mycophenolate sodium, MPA

            14.2.3. Calcineurin Inhibitors

                14.2.3.1. Cyclosporine

                14.2.3.2. Tacrolimus

            14.2.4. mTOR Inhibitors

                14.2.4.1. Sirolimus

                14.2.4.2. Everolimus

            14.2.5. Steroids

                14.2.5.1. Prednisolone

                14.2.5.2. Methylprednisolone

        14.3. Market Value Forecast, by Transplant Type, 2017-2031

            14.3.1. Kidney

            14.3.2. Liver

            14.3.3. Heart

            14.3.4. Lung

            14.3.5. Pancreas

            14.3.6. Others

        14.4. Market Value Forecast, by Distribution Channel, 2017-2031

            14.4.1. Hospital Pharmacies

            14.4.2. Retail Pharmacies

            14.4.3. Online Pharmacies

        14.5. Market Value Forecast, by Country/Sub-region, 2017-2031

            14.5.1. GCC Countries

            14.5.2. South Africa

            14.5.3. Rest of Middle East & Africa

        14.6. Market Attractiveness Analysis

            14.6.1. By Drug Class

            14.6.2. By Transplant Type

            14.6.3. By Distribution Channel

            14.6.4. By Country/Sub-region

    15. Competition Landscape

        15.1. Market Player - Competition Matrix (by tier and size of companies)

        15.2. Market Share Analysis, by Company (2022)

        15.3. Company Profiles

            15.3.1. Pfizer, Inc.

                15.3.1.1. Company Overview

                15.3.1.2. Financial Overview

                15.3.1.3. Product Portfolio

                15.3.1.4. Business Strategies

                15.3.1.5. Recent Developments

            15.3.2. Astellas Pharma, Inc.

                15.3.2.1. Company Overview

                15.3.2.2. Financial Overview

                15.3.2.3. Product Portfolio

                15.3.2.4. Business Strategies

                15.3.2.5. Recent Developments

            15.3.3. Novartis AG

                15.3.3.1. Company Overview

                15.3.3.2. Financial Overview

                15.3.3.3. Product Portfolio

                15.3.3.4. Business Strategies

                15.3.3.5. Recent Developments

            15.3.4. F. Hoffmann-La Roche Ltd.

                15.3.4.1. Company Overview

                15.3.4.2. Financial Overview

                15.3.4.3. Product Portfolio

                15.3.4.4. Business Strategies

                15.3.4.5. Recent Developments

            15.3.5. Sanofi

                15.3.5.1. Company Overview

                15.3.5.2. Financial Overview

                15.3.5.3. Product Portfolio

                15.3.5.4. Business Strategies

                15.3.5.5. Recent Developments

            15.3.6. Bristol-Myers Squibb Company

                15.3.6.1. Company Overview

                15.3.6.2. Financial Overview

                15.3.6.3. Product Portfolio

                15.3.6.4. Business Strategies

                15.3.6.5. Recent Developments

            15.3.7. GlaxoSmithKline plc

                15.3.7.1. Company Overview

                15.3.7.2. Financial Overview

                15.3.7.3. Product Portfolio

                15.3.7.4. Business Strategies

                15.3.7.5. Recent Developments

            15.3.8. AbbVie, Inc.

                15.3.8.1. Company Overview

                15.3.8.2. Financial Overview

                15.3.8.3. Product Portfolio

                15.3.8.4. Business Strategies

                15.3.8.5. Recent Developments

            15.3.9. Hansa Biopharma

                15.3.9.1. Company Overview

                15.3.9.2. Financial Overview

                15.3.9.3. Product Portfolio

                15.3.9.4. Business Strategies

                15.3.9.5. Recent Developments

            15.3.10. WOCKHARDT

                15.3.10.1. Company Overview

                15.3.10.2. Financial Overview

                15.3.10.2. Product Portfolio

                15.3.10.3. Business Strategies

                15.3.10.4. Recent Developments

            15.3.11. Viatris, Inc.

                15.3.11.1. Company Overview

                15.3.11.2. Financial Overview

                15.3.11.3. Product Portfolio

                15.3.11.4. Business Strategies

                15.3.11.5. Recent Developments

            15.3.12. Glenmark

                15.3.12.1. Company Overview

                15.3.12.2. Financial Overview

                15.3.12.3. Product Portfolio

                15.3.12.4. Business Strategies

                15.3.12.5. Recent Developments

            15.3.13. Biocon

                15.3.13.1. Company Overview

                15.3.13.2. Financial Overview

                15.3.13.3. Product Portfolio

                15.3.13.4. Business Strategies

                15.3.13.5. Recent Developments

            15.3.14. Hikma Pharmaceuticals plc

                15.3.14.1. Company Overview

                15.3.14.2. Financial Overview

                15.3.14.3. Product Portfolio

                15.3.14.4. Business Strategies

                15.3.14.5. Recent Developments

            15.3.15. Teva Pharmaceutical U.S.A Inc.

                15.3.15.1. Company Overview

                15.3.15.2. Financial Overview

                15.3.15.3. Product Portfolio

                15.3.15.4. Business Strategies

                15.3.15.5. Recent Developments

            15.3.16. Zydus Pharmaceuticals, Inc.

                15.3.16.1. Company Overview

                15.3.16.2. Financial Overview

                15.3.16.3. Product Portfolio

                15.3.16.4. Business Strategies

                15.3.16.5. Recent Developments

    List of Tables

    Table 01: Global Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Drug Class, 2017‒2031

    Table 02: Global Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Antibodies, 2017‒2031

    Table 03: Global Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Antimetabolites, 2017‒2031

    Table 04: Global Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Calcineurin Inhibitors, 2017‒2031

    Table 05: Global Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by mTOR Inhibitors, 2017‒2031

    Table 06: Global Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Steroids, 2017‒2031

    Table 07: Global Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Transplant Type, 2017-2031

    Table 08: Global Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031

    Table 09: Global Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Region, 2017-2031

    Table 10: North America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Drug Class, 2017‒2031

    Table 11: North America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Antibodies, 2017‒2031

    Table 12: North America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Antimetabolites, 2017‒2031

    Table 13: North America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Calcineurin Inhibitors, 2017‒2031

    Table 14: North America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by mTOR Inhibitors, 2017‒2031

    Table 15: North America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Steroids, 2017‒2031

    Table 16: North America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Transplant Type, 2017-2031

    Table 17: North America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031

    Table 18: North America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Country, 2017‒2031

    Table 19: Europe Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Drug Class, 2017‒2031

    Table 20: Europe Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Antibodies, 2017‒2031

    Table 21: Europe Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Antimetabolites, 2017‒2031

    Table 22: Europe Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Calcineurin Inhibitors, 2017‒2031

    Table 23: Europe Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by mTOR Inhibitors, 2017‒2031

    Table 24: Europe Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Steroids, 2017‒2031

    Table 25: Europe Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Transplant Type, 2017-2031

    Table 26: Europe Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031

    Table 27: Europe Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017‒2031

    Table 28: Asia Pacific Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Drug Class, 2017‒2031

    Table 29: Asia Pacific Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Antibodies, 2017‒2031

    Table 30: Asia Pacific Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Antimetabolites, 2017‒2031

    Table 31: Asia Pacific Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Calcineurin Inhibitors, 2017‒2031

    Table 32: Asia Pacific Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by mTOR Inhibitors, 2017‒2031

    Table 33: Asia Pacific Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Steroids, 2017‒2031

    Table 34: Asia Pacific Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Transplant Type, 2017-2031

    Table 35: Asia Pacific Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031

    Table 36: Asia Pacific Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017‒2031

    Table 37: Latin America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Drug Class, 2017‒2031

    Table 38: Latin America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Antibodies, 2017‒2031

    Table 39: Latin America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Antimetabolites, 2017‒2031

    Table 40: Latin America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Calcineurin Inhibitors, 2017‒2031

    Table 41: Latin America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by mTOR Inhibitors, 2017‒2031

    Table 42: Latin America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Steroids, 2017‒2031

    Table 43: Latin America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Transplant Type, 2017-2031

    Table 44: Latin America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031

    Table 45: Latin America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017‒2031

    Table 46: Middle East & Africa Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Drug Class, 2017‒2031

    Table 47: Middle East & Africa Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Antibodies, 2017‒2031

    Table 48: Middle East & Africa Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Antimetabolites, 2017‒2031

    Table 49: Middle East & Africa Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Calcineurin Inhibitors, 2017‒2031

    Table 50: Middle East & Africa Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by mTOR Inhibitors, 2017‒2031

    Table 51: Middle East & Africa Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Steroids, 2017‒2031

    Table 52: Middle East & Africa Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Transplant Type, 2017-2031

    Table 53: Middle East & Africa Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031

    Table 54: Middle East & Africa Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017‒2031

    List of Figures

    Figure 01: Global Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, 2017-2031

    Figure 02: Global Organ Transplant Rejection Medications Market Value Share, by Drug Class, 2022

    Figure 03: Global Organ Transplant Rejection Medications Market Value Share, by Transplant Type, 2022

    Figure 04: Global Organ Transplant Rejection Medications Market Value Share, by Distribution Channel, 2022

    Figure 05: Global Organ Transplant Rejection Medications Market Value Share Analysis, by Drug Class, 2022 and 2031

    Figure 06: Global Organ Transplant Rejection Medications Market Attractiveness Analysis, by Drug Class, 2023-2031

    Figure 07: Global Organ Transplant Rejection Medications Market Value (US$ Mn), by Antibodies, 2017‒2031

    Figure 08: Global Organ Transplant Rejection Medications Market Value (US$ Mn), by Antimetabolites, 2017‒2031

    Figure 09: Global Organ Transplant Rejection Medications Market Value (US$ Mn), by Calcineurin Inhibitors, 2017‒2031

    Figure 10: Global Organ Transplant Rejection Medications Market Value (US$ Mn), by mTOR Inhibitors, 2017‒2031

    Figure 11: Global Organ Transplant Rejection Medications Market Value (US$ Mn), by Steroids, 2017‒2031

    Figure 12: Global Organ Transplant Rejection Medications Market Value Share Analysis, by Transplant Type, 2022 and 2031

    Figure 13: Global Organ Transplant Rejection Medications Market Attractiveness Analysis, by Transplant Type, 2023-2031

    Figure 14: Global Organ Transplant Rejection Medications Market Revenue (US$ Mn), by Kidney, 2017-2031

    Figure 15: Global Organ Transplant Rejection Medications Market Revenue (US$ Mn), by Liver, 2017-2031

    Figure 16: Global Organ Transplant Rejection Medications Market Revenue (US$ Mn), by Heart, 2017-2031

    Figure 17: Global Organ Transplant Rejection Medications Market Revenue (US$ Mn), by Lung, 2017-2031

    Figure 18: Global Organ Transplant Rejection Medications Market Revenue (US$ Mn), by Pancreas, 2017-2031

    Figure 19: Global Organ Transplant Rejection Medications Market Revenue (US$ Mn), by Others, 2017-2031

    Figure 20: Global Organ Transplant Rejection Medications Market Value Share Analysis, by Distribution Channel, 2022 and 2031

    Figure 21: Global Organ Transplant Rejection Medications Market Attractiveness Analysis, by Distribution Channel, 2023-2031

    Figure 22: Global Organ Transplant Rejection Medications Market Revenue (US$ Mn), by Hospital Pharmacies, 2017-2031

    Figure 23: Global Organ Transplant Rejection Medications Market Revenue (US$ Mn), by Retail Pharmacies, 2017-2031

    Figure 24: Global Organ Transplant Rejection Medications Market Revenue (US$ Mn), by Online Pharmacies, 2017-2031

    Figure 25: Global Organ Transplant Rejection Medications Market Value Share Analysis, by Region, 2022 and 2031

    Figure 26: Global Organ Transplant Rejection Medications Market Attractiveness Analysis, by Region, 2023-2031

    Figure 27: North America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, 2017-2031

    Figure 28: North America Organ Transplant Rejection Medications Market Value Share Analysis, by Drug Class, 2022 and 2031

    Figure 29: North America Organ Transplant Rejection Medications Market Attractiveness Analysis, by Drug Class, 2023-2031

    Figure 30: North America Organ Transplant Rejection Medications Market Value Share Analysis, by Transplant Type, 2022 and 2031

    Figure 31: North America Organ Transplant Rejection Medications Market Attractiveness Analysis, by Transplant Type, 2023-2031

    Figure 32: North America Organ Transplant Rejection Medications Market Value Share Analysis, by Distribution Channel, 2022 and 2031

    Figure 33: North America Organ Transplant Rejection Medications Market Attractiveness Analysis, by Distribution Channel, 2023-2031

    Figure 34: North America Organ Transplant Rejection Medications Market Value Share Analysis, by Country, 2022 and 2031

    Figure 35: North America Organ Transplant Rejection Medications Market Attractiveness Analysis, by Country, 2023-2031

    Figure 36: Europe Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, 2017-2031

    Figure 37: Europe Organ Transplant Rejection Medications Market Value Share Analysis, by Drug Class, 2022 and 2031

    Figure 38: Europe Organ Transplant Rejection Medications Market Attractiveness Analysis, by Drug Class, 2023-2031

    Figure 39: Europe Organ Transplant Rejection Medications Market Value Share Analysis, by Transplant Type, 2022 and 2031

    Figure 40: Europe Organ Transplant Rejection Medications Market Attractiveness Analysis, by Transplant Type, 2023-2031

    Figure 41: Europe Organ Transplant Rejection Medications Market Value Share Analysis, by Distribution Channel, 2022 and 2031

    Figure 42: Europe Organ Transplant Rejection Medications Market Attractiveness Analysis, by Distribution Channel, 2023-2031

    Figure 43: Europe Organ Transplant Rejection Medications Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

    Figure 44: Europe Organ Transplant Rejection Medications Market Attractiveness Analysis, by Country/Sub-region, 2023-2031

    Figure 45: Asia Pacific Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, 2017-2031

    Figure 46: Asia Pacific Organ Transplant Rejection Medications Market Value Share Analysis, by Drug Class, 2022 and 2031

    Figure 47: Asia Pacific Organ Transplant Rejection Medications Market Attractiveness Analysis, by Drug Class, 2023-2031

    Figure 48: Asia Pacific Organ Transplant Rejection Medications Market Value Share Analysis, by Transplant Type, 2022 and 2031

    Figure 49: Asia Pacific Organ Transplant Rejection Medications Market Attractiveness Analysis, by Transplant Type, 2023-2031

    Figure 50: Asia Pacific Organ Transplant Rejection Medications Market Value Share Analysis, by Distribution Channel, 2022 and 2031

    Figure 51: Asia Pacific Organ Transplant Rejection Medications Market Attractiveness Analysis, by Distribution Channel, 2023-2031

    Figure 52: Asia Pacific Organ Transplant Rejection Medications Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

    Figure 53: Asia Pacific Organ Transplant Rejection Medications Market Attractiveness Analysis, by Country/Sub-region, 2023-2031

    Figure 54: Latin America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, 2017-2031

    Figure 55: Latin America Organ Transplant Rejection Medications Market Value Share Analysis, by Drug Class, 2022 and 2031

    Figure 56: Latin America Organ Transplant Rejection Medications Market Attractiveness Analysis, by Drug Class, 2023-2031

    Figure 57: Latin America Organ Transplant Rejection Medications Market Value Share Analysis, by Transplant Type, 2022 and 2031

    Figure 58: Latin America Organ Transplant Rejection Medications Market Attractiveness Analysis, by Transplant Type, 2023-2031

    Figure 59: Latin America Organ Transplant Rejection Medications Market Value Share Analysis, by Distribution Channel, 2022 and 2031

    Figure 60: Latin America Organ Transplant Rejection Medications Market Attractiveness Analysis, by Distribution Channel, 2023-2031

    Figure 61: Latin America Organ Transplant Rejection Medications Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

    Figure 62: Latin America Organ Transplant Rejection Medications Market Attractiveness Analysis, by Country/Sub-region, 2023-2031

    Figure 63: Middle East & Africa Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, 2017-2031

    Figure 64: Middle East & Africa Organ Transplant Rejection Medications Market Value Share Analysis, by Drug Class, 2022 and 2031

    Figure 65: Middle East & Africa Organ Transplant Rejection Medications Market Attractiveness Analysis, by Drug Class, 2023-2031

    Figure 66: Middle East & Africa Organ Transplant Rejection Medications Market Value Share Analysis, by Transplant Type, 2022 and 2031

    Figure 67: Middle East & Africa Organ Transplant Rejection Medications Market Attractiveness Analysis, by Transplant Type, 2023-2031

    Figure 68: Middle East & Africa Organ Transplant Rejection Medications Market Value Share Analysis, by Distribution Channel, 2022 and 2031

    Figure 69: Middle East & Africa Organ Transplant Rejection Medications Market Attractiveness Analysis, by Distribution Channel, 2023-2031

    Figure 70: Middle East & Africa Organ Transplant Rejection Medications Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

    Figure 71: Middle East & Africa Organ Transplant Rejection Medications Market Attractiveness Analysis, by Country/Sub-region, 2023-2031

Copyright © Transparency Market Research, Inc. All Rights reserved